[Featured Stock] SK Bioscience Rises on Strong Expectations for Second Half Performance

[Asia Economy Reporter Song Hwajeong] SK Bioscience is showing a strong performance with a gain of over 6% due to its solid second-quarter results and expectations for the second half of the year.

As of 9:41 AM on the 2nd, SK Bioscience was trading at 182,000 KRW, up 11,500 KRW (6.74%) from the previous day.

SK Bioscience recorded second-quarter sales of 144.6 billion KRW, a 277.2% increase compared to the same period last year, and operating profit turned positive at 66.2 billion KRW. The outlook suggests even better performance in the second half. Park Byung-guk, a researcher at NH Investment & Securities, said, "The results will be better in the second half," adding, "Sales from the Novavax government contract for 40 million doses are expected to begin in earnest from the second half."